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Side effectsAbstract Introduction: Female germ cell tumors (GCTS) are rare tumors that carry a good
prognosis.
Aim: To report the experience of the Egyptian National Cancer Institute (ENCI) in managing
female GCTs.
Methods: This retrospective study included 19 females with ovarian GCTs presenting to the ENCI
between 2006 and 2010.
Results: The median age was 23 years. Ovaries were the primary site in all patients. Dysgerminoma
and teratoma were the predominant pathologies followed by mixed GCT in females. Unilateral
ovariectomy or ovarian tumorectomy were the classic surgical procedures with R0 resection being
feasible in most cases. Surveillance was adopted in six patients with stage I disease. Chemotherapy
was administered in 63% of ovarian GCTs with BEP being the commonest regimen with reasonable
tolerability and good response rates. The median OS and EFS were not reached. The projected
5-year OS rate was 93.8%. Both OS and EFS were better in patients responding to chemotherapy
than non-responders (p< 0.002). Stage of disease did not signiﬁcantly affect OS or EFS.
Conclusions: Female GCTs rarely affect Egyptian females. They have good prognosis.
ª 2014 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.D license.Introduction
Non-epithelial ovarian malignancies account for about 10%
of all ovarian cancers. Ovarian germ cell tumors (GCTs)
represent 5% of all ovarian cancers and are mostly diag-
nosed in young women [1]. The yearly adjusted incidence
rate is 3.7/1000000 [2]. In Egypt and at the population level,
ovarian GCTs constitute 10% of ovarian tumors [3]. At the
Egyptian National Cancer Institute, ovarian GCTs consti-
tute 12.6% of ovarian tumors [4]. Ovarian GCTs include
Table 1 Characteristics of female patients with germ cell
tumors at ENCI.
N (%)
Total 19 (100.0)
Median age (range) years 23 (18–68)
Presentation
Swelling 6 (31.6)
Pain 6 (31.6)
Unknown 8 (42.1)
Primary site
Gonadal 19 (100.0)
Extra-gonadal 0 (0)
Pathology
Dysgerminoma 9 (47.4)
Teratoma 9 (47.4)
Mixed GCT 1 (5.2)
Stage
I 12 (63.2)
II 2 (10.5)
III 5 (26.3)
Surgery
Ovariectomy 12 (63.2)
Ovarian cystectomy 7 (36.8)
Surgical residual
R0 11 (57.9)
R2 1 (5.3)
Unknown 7 (36.8)
Chemotherapy
Yes 12 (63.2)
No 6 (31.6)
Unknown 1 (5.2)
First-line chemotherapy regimen
BEP 11 (91.7)
Paclitaxel/carboplatin 1 (7.7)
Chemotherapy response
CR 9 (75)
PD 1 (8.3)
NA 2 (16.7)
Relapse
RP/PALN 1 (5.3)
Pelvis and liver 1 (5.3)
Chemotherapy on relapse/progression
BEP 2 (10.6)
Ifosfamide/epirubicin 1 (5.3)
Paclitaxel/carboplatin 1 (5.3)
Abbreviations: GCT: germ cell tumor. R0: no residual, R2: gross
residual, OS: overall survival. DFS: disease free survival. PFS:
progression-free survival. CR: complete remission. S.D: stable
disease. P.D: progressive disease. PR: partial response OR: objec-
tive response. TAH+ BSO: total abdominal hysterectomy and
bilateral salpingo-oophorectomy. Ctx: chemotherapy.
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(yolk sac) tumours, embryonal carcinomas, polyembryomas,
choriocarcinomas, teratomas, and mixed GCTs [5]. The
majority of GCTs (60–70%) are diagnosed at an early stage.
Stage I patients have an excellent prognosis with long-term
disease free status in >90% of cases [6]. Patients with stage
IA grade 1 immature teratoma do not require further adju-
vant chemotherapy after adequate surgical staging [7]. Also,
stage IA pure dysgerminomas can be treated solely with sur-
gery with a relatively low recurrence rate (15–25%) that can
be successfully treated at the time of relapse with a high
likelihood of cure [6]. Owing to their exquisite chemo-sensi-
tivity, fertility-sparing surgery should be considered also in
advanced stage disease with a cure rate of >95%. Patients
should undergo debulking surgery to remove as much gross
tumor as possible, but without major extensive procedures
because of the high chemo-sensitivity of these tumors and
the high cure [8].
Platinum-based chemotherapy regimens have been the
treatment of choice and the BEP regimen is the most widely
used one [9,10]. BEP is usually administered for three cycles
in patients with completely resected disease and for four cycles
in patients with macroscopic residual disease. However, there
is no consensus as to the optimal duration of therapy [6]. Pa-
tients resistant to a cisplatin-based combination may receive
vincristine–actinomycin D–cyclophosphamide (VAC) [10] or
paclitaxel–gemcitabine as salvage therapy [11]. The role of sec-
ondary cytoreductive surgery in patients with recurrent or pro-
gressive ovarian GCTs remains controversial. It may have
some beneﬁts for a selected group of patients, particularly
those with immature teratoma and a growing teratoma syn-
drome [6].
Little is known about ovarian GCTs in Egypt. Thus, we
conducted this study to report the clinico-pathological fea-
tures, treatments and outcomes of ovarian GCTs at the biggest
Egyptian Cancer Center.
Patients and methods
This retrospective study included 19 females having ovarian
GCTs at the Egyptian National Cancer Institute (NCI),
Cairo University between the January 2006 and December
2010. The study was approved by the Ethics Committee of
the Egyptian NCI. Relevant information was extracted from
the medical records. These included subjects’ demographics,
clinical and pathological characteristics, treatments and their
outcomes.
Statistical analyses
Statistical analyses were done using SPSSª win statistical
package version 17. Survival analyses were done using the
Kaplan–Meier method. Comparisons between two survival
curves were done using log-rank test. A p-value <0.05
was considered statistically signiﬁcant. Overall survival
(OS) was deﬁned as the time in months between the date
of diagnosis and death or loss to follow up. Event-free sur-
vival (EFS) was deﬁned as the time in months between the
date of treatment and documented recurrence, progression
or death.Results
This study included 19 female patients with germ cell tumors
treated at the Egyptian National Cancer Institute during the
years 2006–2010.
Patients’ characteristics
Age ranged between 18 and 68 years with a median of
23 years. Almost 95% of patients (18 patients) were below
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local pains were documented in 31.6%, each. One patient
had a history of acute lymphoblastic leukemia, another
one had ovarian dermoid cyst and a third one had a family
history of osteosarcoma. The primary site for GCTs was the
gonads in all cases. Dysgerminoma and teratoma were the
predominant pathologies. All patients were surgically as-
sessed with unilateral ovariectomy being the most common
surgical procedures. It was associated with hysterectomy
(i.e. TAH/BSO) in two patients with the diagnosis of malig-
nant teratoma and stage IIIC disease having extensive peri-
toneal metastases outside the pelvis. One patient was
68 years old and postmenopausal and thus fertility preserva-
tion was not applicable. The other patient was 35 years and
the diagnosis of GCTs was done postoperatively. Complete
surgical resection (R0) was the rule. Most patients (63%)
were diagnosed early at stage I. Following surgery, 6 pa-
tients were put under surveillance and only one of them
developed relapse later on and received BEP chemotherapy
and achieved CR.
Chemotherapy was administered in 12 patients (63%)
and BEP was the commonest regimen that was used in
92% of cases. The median number of cycles was 4 (range,
1–6). Beyond 4 cycles, bleomycin was omitted. Toxicity was
documented only in 5 patients and was mostly hematologic
(neutropenia). None has documented pulmonary toxicity. At
the end of chemotherapy, 75% of patients were maintained
in complete remission. Two patients received second-line
chemotherapy being ifosfamide/epirubicin in one patient
and paclitaxel/carboplatin in other patient. One patient
relapsed from CR after ﬁrst-line paclitaxel/carboplatin. She
received BEP and had PD.Figure 1 OS of femaleOverall survival
The follow up period ranged between 1 and 120 months with a
median of 33 months. At the last follow up visit, one patient
was dead and 18 patients were alive. The median OS was not
reached (Fig. 1). The 2-year OS rate was 93.8%. The impact
of different confounders on OS was explored (Table 2). Re-
sponse to chemotherapy was signiﬁcantly associated with OS.
Event free survival (EFS)
Due to the small number of relapses in only two cases, com-
parison of DFS did not yield useful information. Rather, we
performed a comparison based on EFS (Table 2). Events were
deﬁned as death, recurrence or progression of the disease. The
median EFS was not reached (Fig. 2). The 2-year EFS rate was
73%. The impacts of different confounders on EFS were ex-
plored (Table 2). Response to chemotherapy was signiﬁcantly
associated with EFS.
Discussion
This retrospective study was conducted at the Egyptian NCI in
a 5-year period between January 2006 and December 2010. It
aimed to study female GCT’s, their treatments and the impact
on EFS and OS. This study included 19 female patients with
ovarian GCTs.
At the NCI, ovarian germ cell tumors constituted 12.6% of
ovarian tumors [4], compared to the 10% ﬁgure reported by
Smith et al. [1]. In our study, the median age was 23 years
(range 18–68 years), which was higher than 19 years reportedpatients with GCTs.
Table 2 Overall and event-free survival of female germ cell tumors.
Group N Overall survival Event-free survival
2YSR (SE) P 2YSR (SE) P
All 19 93.8 (6.1) – 73.0 (10.4) –
Year
2006–2008 8 85.7 (13.2) 62.5 (17.1)
2009–2010 11 100 (0) 0.257 80.8 (12.2) 0.361
Pathology
Dysgerminoma 9 100 (0) 77.8 (13.9)
Teratoma 9 85.7 (13.2) 0.285 64.8 (16.5) 0.531
Stage
I 12 100 (0) 82.5 (11.3)
II + III 7 83.3 (15.2) 0.197 57.1 (18.7) 0.217
Surgery
Complete ovariectomy 10 100 (0) 80.0 (12.6)
Partial ovariectomy 7 100 (0) – 85.7 (13.2) 0.827
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70% of ovarian tumours are of germ-cell origin, and one-third
of these are malignant [13].
The most common risk factor of ovarian GCT’s is dysge-
netic gonads so a preoperative karyotype is recommended on
all pre-menarche girls because of the propensity of these
tumors [14]. In the current study, Karyotyping was not
performed given the retrospective nature of the study and
being not the standard of care. We only documented an
association with a history of acute lymphoblastic leukemia in
one patient and a dermoid cyst in another one.
In the current study, teratomas and dysgerminomas were
the most common pathologies. This is similar to past reports
of ENCI [4] and European data showing those teratomas areFigure 2 Event free survival (EFSthe most common GCTs [6]. Clinical presentations (swelling
and pain) and earlier stage at diagnosis were similar to those
reported in the literature [6].
In the current study, fertility preservation surgery was
achieved in 17 patients. However, two patients had TAH/
BSO. One was in the postmenopausal period (68 years) while
the other was 35 years of age (and completed her family with
3 children) and both were stage IIIC, with teratoma histology.
This is similar to the published guidelines where unilateral
salpingo-oophorectomy with preservation of the contralateral
ovary and the uterus is considered the adequate surgical treat-
ment for patients with GCTs [15,16]. In women with advanced
disease (e.g. para-aortic lymph-node metastases), preservation
of reproductive function is also possible, particularly if the) of female patients with GCTs.
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stage IA were kept under surveillance (3 had teratoma and 3
had dysgerminoma). This goes with the international guide-
lines e.g. ESMO and NCCN that advocate that stage IA pure
dysgerminoma can be treated with surgery only. Recurrence
rate in this group of patients is relatively low (15–25%) and
they can be successfully treated at the time of relapse with a
high likelihood of cure [6]. Some published data indicate that
all grades of immature teratoma can be managed with close
surveillance after fertility-sparing surgery, reserving chemo-
therapy for those cases in which post-surgery recurrence is
documented [19]. Only one of the 6 followed-up cases relapsed
after 17 months and achieved CR after receiving BEP for 4
cycles.
In the current study, no cases received radiotherapy despite
the high radio-sensitivity of dysgerminomas. Historically,
radiotherapy was used in many stage I dysgerminomas and
in all patients having higher stage tumors with the ﬁeld and
dose determined by the stage [20]. However, this approach
has many reported long-term toxicities [21,22]. In the current
routine practice, radiotherapy is rarely performed since che-
motherapy is equally or more effective, less toxic and less likely
to compromise gonadal function [22].
Whenever indicated, platinum-based combination chemo-
therapy is the norm both in the early as well as in the advanced
stages of ovarian GCTs with BEP ranking the ﬁrst regimen
[6,9]. Data from the current study ﬁt within these norms. Che-
motherapy was administered in 63% of cases; 6 had teratoma
and 6 had dysgerminoma {6 cases had stage I, 2 cases had
stage II, and 4 cases had stage III}. BEP was the commonest
regimen used (91.7%). In the current study, two teratoma pa-
tients received second-line chemotherapy either ifosfamide/epi-
rubicin or paclitaxel carboplatin with poor response. This
reﬂects the poor management of women who have persistent/
resistant disease after ﬁrst-line chemotherapy or who progress
within 4–8 weeks of completing adjuvant treatment. Results
with salvage regimens and high-dose chemotherapy are poor
in the setting of platinum-refractory disease [23].
Relapses were documented in two patients reﬂecting the
good prognosis of this disease. One had stage III teratoma
and received paclitaxel/carboplatin as ﬁrst-line and relapsed
17 months after end of therapy. The other patient had stage
IA dysgerminoma under active surveillance and relapsed
12 months after surgery. Both received BEP. Relapse site
was para aortic LN’s and pelvis and this is different from
the usual presentation as 75% of GCT recurrences occur with-
in the ﬁrst year after initial treatment and the most common
site is the peritoneal cavity, more rarely retroperitoneal lymph
nodes [6].
In the current study, the median OS was not reached reﬂect-
ing the good prognosis. Better survival with early compared to
late stage disease was reported in the series by Rogers et al.
[24]. However similar to Talukdar et al. [12], we reported lack
of OS difference between early and late stage disease. The
small number of cases in the current study may explain for
such differences. Similar to the experience by the GOG [23],
completely resected patients (R0) had better OS than those
who had residual after surgery. Also, patients responding to
chemotherapy have signiﬁcantly better 5-year OS rates
(100%) than non-responders (0%). The lower EFS of patients
with stage I ovarian GCTs in the current study compared to
the published ﬁgures (82.5% vs. more than 90%), may bedue to the small absolute numbers. Similar to that reported
to Williams et al. [25] and Williams et al. [26], patients with
no residual after surgery had signiﬁcantly better EFS than
those with gross residual.
To the best of our knowledge, our study is the one of the
very few to report on GCTs both in Egypt and worldwide.
Our study has also some limitations that include being retro-
spective in nature and having some missing information. How-
ever, such a rare disease is best followed within such
retrospective studied as prospective collection of enough num-
ber of patients will take long time and need the collaboration
of many centers.
Conclusions and recommendations
The current study conﬁrmed that FGCTs are rare tumors that
affect young Egyptian patients. It also conﬁrmed the good out-
come of therapy. As shown in this study, patients with GCTs
have a long survivorship and many are cured of their disease.
Thus, long-term follow up is needed to follow these patients
for the delayed effects of treatments. Herein, long-term follow
up was suboptimal and this mandates consideration and plan-
ning to overcome. GCT patients can play a vital role in sup-
porting other cancer patients through provision of personal
experiences and encouragement. They can be good advocates
for patients and the Institute. Finally, we are in need of multi-
center and multinational prospective analysis of treatment op-
tions for this disease over several years with a large number of
patients to understand their successes and failures.
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